1 ~~4~~. (Third Amendment) A method for the diagnosis of ABPA in a human individual, comprising determining if the individual carries antibodies reactive with one or more ABPA-related recombinant allergens, which one or more ABPA-related recombinant allergens discriminate between ABPA and allergic sensitization to *A. fumigatus and* wherein the one or more allergens are selected from the group consisting of rAsp f4 and rAsp f6, and ABPA-related fragments thereof which bind with IgE or IgG antibody.

D2

2 ~~3~~. (Third Amendment) A method for the diagnosis of ABPA in a human individual, comprising determining if the individual carries antibodies reactive with one or more ABPA-related recombinant allergens, which one or more ABPA-related recombinant allergens discriminate between ABPA and allergic sensitization to *A. fumigatus and* wherein the one or more allergens are selected from the group consisting of rAsp f8 and ABPA-related fragments thereof which bind with IgE or IgG antibody.

13 ~~16~~. (Twice Amended) A method for the diagnosis of ABPA in a human individual, comprising determining if the individual carries antibodies reactive with one or more ABPA-related recombinant allergens, which one or more ABPA-related recombinant allergens discriminate between ABPA and allergic sensitization to *A. fumigatus,* wherein the allergen is derived from *A. fumigatus* and wherein the one or more allergens are selected from the group consisting of rAsp f4 and rAsp f6, and ABPA-related fragments thereof which bind with IgE or IgG antibody.

D3

14 ~~17~~. (Twice Amended) The method according to claim 13 ~~16~~, wherein the one or more allergens are selected from the group consisting of rAsp f4 and rAsp f6.

22 1 G
gnd 3/7/03
PATENT AE.

Docket No. 10806-93
CERTIFICATE OF FACSIMILE
I hereby certify that this paper is being transmitted via facsimile to Group Art Unit 1644, Examiner P. Nolan; Box AF; Commissioner of Patents; Washington, DC 20231, at facsimile number 703-308-2742 on March 4, 2003.

Holly D Kaylor

—Expedited Processing
Amendment Under 37 CFR 1.116—

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:	Reto CRAMERI et al	:	Paper No.:
Serial No.:	09/319,806	:	Group Art Unit: 1644
Filed:	August 19, 1999	:	Examiner: P. Nolan

For: **Methods for Diagnosis of Allergic Bronchopulmonary Aspergillosis**

SECOND AMENDMENT UNDER 37 C.F.R. 1.116

Box AF
Commissioner for Patents
Washington, DC 20231

O.K. to enter P.N. 4/1/03

Dear Sir:

In response to the Official Action dated November 4, 2002 and the Advisory Action dated February 13, 2003, please amend the present application as follows:

In the Claims:

Please cancel claims 1-3.

Please amend claims 6-9 to read as follows:

3 6. (Twice Amended) The method according to claim 1, wherein an in vitro immunoassay is carried out on a fluid sample from the individual for the determination of the level of antibodies directed towards said recombinant allergens.

G1

4 7. (Twice Amended) The method according to claim 1, wherein antibodies of the IgE class are determined.

C-2 5 ~~8~~. (Twice Amended) The method according to claim ~~1~~ 1, wherein an in vivo test is carried out in the individual.

C-3 6 ~~9~~. (Third Amended) The method according to claim ~~1~~ 5, wherein the test is a skin test involving placing said one or more ABPA-related recombinant allergens in the skin of the patient.

3. (AMENDED) The method according to claim 2, [characterized in that] wherein the allergen [correspond] corresponds to a non-secreted protein from A. fumigatus.

4. (AMENDED) The method according to claim 1, wherein the [anyone of claims 1-3, characterized in that said] one or more allergens are selected [among] from the group consisting of rAsp f4 and rAsp f6, and ABPA-related fragments thereof.

5. (AMENDED) The method according to claim 1, wherein the [anyone of claims 1-3, characterized in that said] one or more allergens are selected [among] from the group consisting of rAsp f8 and ABPA-related fragments thereof.

6. (AMENDED) The method according to claim 1, wherein [anyone of claims 1-4, characterized in that] an in vitro immunoassay is carried out on a fluid sample from the individual for the determination of the level of antibodies directed towards said recombinant allergens[, in particular antibodies of the IgE class or IgG class or subclasses thereof].

7. (AMENDED) The method according to claim 1, wherein [anyone of claims 1-5, characterized in that] antibodies of the IgE class are determined.

8. (AMENDED) The method according to claim 1, wherein [anyone of claims 1-4, characterized in that] an in vivo test is carried out in the individual.

9. (AMENDED) The method according to claim 7, [characterized in that] wherein the test is a skin test involving placing said ~~one or more~~ ABPA-related allergens in the skin of the patient.

10. (AMENDED) The method according to claim ~~9~~, [characterized in that] wherein an in vitro immunoassay is carried out on a fluid sample from the individual for the determination of the level of antibodies directed towards said recombinant allergens[, in particular antibodies of the IgE class or IgG class or subclasses thereof].

8 7
11. (AMENDED) The method according to claim 10, [characterized in that] wherein antibodies of the IgE class are determined.

9 2
12. (AMENDED) The method according to claim 5, [characterized in that] wherein an in vivo test is carried out in the individual.

10 9
13. (AMENDED) The method according to claim 12, [characterized in that] wherein the test is a skin test involving placing said one or more ABPA-related allergens in the skin of the patient.

Please add the following claims 14-20:

11 3
--14. (NEW) The method according to claim 8, wherein antibodies of the IgE class or IgG class, or subclasses thereof, are determined.--

12 7
--15. (NEW) The method according to claim 10, wherein antibodies of the IgE class or IgG class, or subclasses thereof, are determined.--

--16. (NEW) The method according to claim 2, wherein the one or more allergens are selected from the group consisting of rAsp f4 and rAsp f6, and ABPA-related fragments thereof.--

--17. (NEW) The method according to claim 3, wherein the one or more allergens are selected from the group consisting of rAsp f4 and rAsp f6, and ABPA-related fragments thereof.--

--18. (NEW) The method according to claim 2, wherein the one or more allergens are selected from the group consisting of rAsp f8, and ABPA-related fragments thereof.--

--19. (NEW) The method according to claim 3, wherein the one or more allergens are selected from the group consisting of rAsp f8, and ABPA-related fragments thereof.--

17 15
--20. (NEW) The method according to claim 18, wherein an in vivo test is carried out in the individual.--

15
~~18~~. (Twice Amended) A method for the diagnosis of ABPA in a human individual, comprising determining if the individual carries antibodies reactive with one or more ABPA-related recombinant allergens, which one or more ABPA-related recombinant allergens discriminate between ABPA and allergic sensitization to *A. fumigatus,* wherein the allergen is derived from *A. fumigatus* and wherein the one or more allergens are selected from the group consisting of rAsp f8, and ABPA-related fragments thereof which bind with IgE or IgG antibody.

16 15
~~19~~. (Twice Amended) The method according to claim ~~18~~, wherein the allergen is rAsp f8.